Joint Formulary & PAD

Tocilizumab - Covid-19

You are here : Home > Formulary Search > Tocilizumab - Covid-19

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Infusion
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NICE
SPC
Restrictions / Comments :

Documentation

Evidence Review
NICE TA878 CMDU APC briefing paper Jun-23.doc
Webpage
NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
Information
CMDU Community Pharmacies June 2025.pdf
Information
Covid Medicines Delivery Unit - Update re provision - June 2025.pdf

PAD Profile

ChemicalSubstance :
Tocilizumab
Indication :
Covid-19
Group Name :
Keywords :
CMDU, covid medicines delivery unit, monoclonal antibody, MAB,
Brand Names Include :
RoActemRA, Tyenne
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
4

Committee Recommendations (1)

05 Jul 23 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey Heartland Integrated Care System Area Prescribing Committee agree implementation of NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19.

Tocilizumab is agreed as  RED only for administration in the hospital setting
 

Other Indications

Below are listed other indications that Tocilizumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Covid-19.